Ge Long Hui·2026-02-09 09:18Core Viewpoint - Novo Nordisk (NVO.US) shares rose by 6.6% to $50.79, while Hims & Hers Health (HIMS.US) shares fell nearly 14% to $19.81 following the announcement regarding a generic weight loss drug [1] Group 1: Company Actions - Hims & Hers Health announced the removal of its $49 generic weight loss drug from the market [1] - The company had launched the generic weight loss drug, which was approximately $100 cheaper than Novo Nordisk's Wegovy [1] - Hims & Hers stated that it has engaged in constructive dialogue with industry stakeholders since the launch of the generic semaglutide pill and has decided to cease offering the treatment [1] Group 2: Regulatory and Legal Responses - Novo Nordisk issued a statement warning about the significant risks associated with the illegal Wegovy compound formulation and announced plans to take legal action against Hims & Hers [1] - The U.S. Food and Drug Administration (FDA) also issued a warning to Hims & Hers regarding the generic drug [1]